Colorectal Clinical Trials

Colorectal Cancer (ARC-9)

Overview

A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.

Key Eligibility Criteria

Histologically confirmed metastatic colorectal adenocarcinoma
Inclusion Criteria for Cohort A:
- Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent
Inclusion Criteria for Cohort B:
- Disease progression during or following not more than two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent
Inclusion Criteria for Cohort C:
- Disease progression during or following more than three separate lines of treatment for mCRC

ARC-9 Clinical Trial Locations

clinicaltrials.gov

Healthcare Professionals: to learn more about Arcus trials, email [email protected]

Patients and Caregivers: Talk to your doctor if you are interested in learning more about Arcus clinical trials.

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration or by any health authority.